Every 424B that Neuphoria Therapeutics Inc. (NEUP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NEUP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEUP filings page.
Neuphoria Therapeutics Inc. filed Amendment No. 7 to its prospectus supplement, updating its at‑the‑market program to offer and sell up to $20,000,000 of common stock from time to time through H.C. Wainwright & Co. as sales agent, under Rule 415(a)(4).
The company notes its public float exceeded $75.0 million beginning on November 3, 2025, so it is no longer limited by Form S‑3 “baby shelf” constraints; this amendment increases and fixes the continuous offering size at $20,000,000 as of the amendment date. Wainwright will use commercially reasonable efforts with no minimum sales requirement and will receive a 3.0% commission on the gross sales price per share. NEUP is listed on Nasdaq; the last reported sale price was $4.75 on November 13, 2025.
Neuphoria Therapeutics (NEUP) filed Amendment No. 6 to its prospectus supplement for its at-the-market program, permitting sales of up to $21,917,873 of common stock from time to time through H.C. Wainwright as sales agent.
Sales will be effected as an “at the market” offering under Rule 415(a)(4). Wainwright will receive a 3.0% commission on gross proceeds and will be deemed an underwriter; indemnification and contribution apply. The company states compliance with General Instruction I.B.6 of Form S‑3: public float was approximately $65,753,620 based on 3,287,681 non‑affiliate shares at $20.00 as of October 6, 2025, and it has sold $15,477,836 over the past 12 months under I.B.6.
The common stock trades on Nasdaq as NEUP; the last reported sale price was $6.24 on October 24, 2025.
NeuroBo Pharmaceuticals (NEUP) amended its prospectus supplement to update its at-the-market program, allowing sales of up to $15,478,160 of common stock from time to time through H.C. Wainwright & Co. as sales agent under a previously executed Sales Agreement. Sales may be made in transactions deemed an at-the-market offering under Rule 415(a)(4).
The update reflects eligibility under General Instruction I.B.6 of Form S-3, which limits primary sales to no more than one-third of public float in any 12-month period while public float is below $75 million. Public float was $46,434,480, based on 2,321,724 non-affiliate shares at $20.00 as of October 6, 2025. In the past 12 months, the company sold $5,352,879 under I.B.6. Wainwright earns a 3.0% commission on gross proceeds.
Nasdaq-listed company plans to sell up to $11,494,900 of common stock from time to time through an at-the-market offering agreement with H.C. Wainwright & Co. as sales agent.
This amendment updates the prospectus supplement to reflect the amount of stock the company may sell under General Instruction I.B.6 of Form S-3 and the existing Sales Agreement. As of September 9, 2025, public float was approximately $34,484,701, based on 2,283,755 non-affiliate shares at $15.10 per share, and the company has sold $5,352,879 of common stock under this instruction in the past 12 months.
Sales, if any, will be made as at-the-market offerings under Rule 415, with no minimum sale requirements, and Wainwright earning a 3.0% commission on gross sales while being deemed an underwriter under the Securities Act.